NPH Insulin: Dosing, Comparisons, and What to Expect

What Is NPH Insulin and How Does It Work?

NPH insulin is a suspension of human insulin complexed with protamine and zinc to slow its absorption from the subcutaneous tissue. The word "NPH" stands for Neutral Protamine Hagedorn, named after Hans Christian Hagedorn, who developed the formulation in 1946. Because the protamine crystal must dissolve before insulin enters the bloodstream, absorption is delayed compared with rapid-acting analogs, placing NPH squarely in the intermediate-acting category [1].

After a subcutaneous injection, NPH begins lowering blood glucose within 1 to 2 hours. Activity peaks between 4 and 12 hours and then tapers over a total of 18 to 24 hours. That pronounced peak is both a clinical feature and a limitation: it can effectively cover a meal or suppress hepatic glucose output overnight, yet it also creates a hypoglycemia window that longer-acting analogs like insulin glargine (Lantus, Basaglar) largely avoid [2].

The FDA-approved labeling for Humulin N notes that the time-action profile varies significantly between patients and even between injections in the same patient, depending on injection site, local blood flow, and body temperature [3]. Clinicians should keep that variability in mind when titrating doses for individual patients.

NPH is a recombinant human insulin, not a synthetic analog. Its amino acid sequence is identical to endogenous insulin, which matters for immunogenicity: the rate of anti-insulin antibody formation is low but higher than with some modern analogs [4].

FDA Approval Status, Brand Names, and OTC Availability

The FDA approved Humulin N in 1982 and Novolin N in 1991 [3]. Both carry FDA Pregnancy Category B designations based on animal data and extensive clinical experience in gestational diabetes [5].

In the United States, Humulin N and Novolin N are legally available without a prescription under FDA guidance that grandfathered certain human insulins as OTC products. Walmart sells Novolin N under the ReliOn label for roughly $25 per 10 mL vial (100 units per mL), making it one of the few insulins accessible to uninsured patients [6]. The 2023 American Diabetes Association Standards of Care explicitly acknowledge OTC insulin access as a safety-net option while cautioning that patients should still have medical supervision when possible [7].

A 3 mL prefilled pen version (KwikPen for Humulin N) requires a prescription in most states and costs substantially more without insurance coverage.

Standard Dosing Protocols for Type 1 and Type 2 Diabetes

For type 2 diabetes, the ADA recommends starting basal insulin at 10 units per day or 0.1 to 0.2 units per kg per day, then titrating by 2 units every 3 days until fasting glucose is consistently between 80 and 130 mg/dL [7]. NPH is commonly given once daily at bedtime to cover overnight hepatic glucose production, or twice daily (before breakfast and at bedtime) to provide broader coverage throughout the day [8].

The UKPDS 57 substudy (N=826 with type 2 diabetes) found that twice-daily NPH achieved a mean HbA1c of 7.1% over 6 years in patients receiving insulin as their primary therapy, compared with 7.9% in those managed with oral agents alone (P<0.001) [9]. Reaching that target required a median total daily dose of 60 units, split into two injections.

For type 1 diabetes, NPH is used as the basal component of a mixed regimen, most often paired with regular human insulin. A common split-mixed schedule delivers 60 to 70 percent of the total daily dose as NPH (split into morning and bedtime injections) and 30 to 40 percent as preprandial regular insulin [1]. Basal-bolus regimens using insulin analogs have largely replaced this approach in well-resourced settings, but NPH-based regimens remain the global standard in low- and middle-income countries where analogs are unaffordable [10].

Dose adjustments should be guided by structured glucose monitoring. The American Association of Clinical Endocrinology (AACE) 2022 Diabetes Management Algorithm recommends fasting and 2-hour postprandial targets of <100 mg/dL and <140 mg/dL respectively for most adults without significant hypoglycemia risk [11].

Mixing NPH with Regular Insulin: Rules and Sequence

NPH can be mixed with regular human insulin (e.g., Humulin R, Novolin R) in the same syringe. The correct sequence is: draw regular insulin first, then draw NPH. Reversing that order risks contaminating the regular insulin vial with protamine, which would change its time-action profile [1].

Pre-mixed formulations like Humulin 70/30 (70% NPH, 30% regular) and Novolin 70/30 eliminate mixing errors and improve adherence, but they sacrifice the flexibility to adjust the two components independently [3]. The FDA labels for these mixtures specify that the fixed-ratio formulations should not be used in insulin pumps or given intravenously [3].

NPH should never be mixed with insulin analogs (glargine, detemir, degludec, lispro, aspart, glulisine). Mixing with glargine, for example, raises the pH of the glargine solution and causes precipitation, reducing its duration of action unpredictably [2].

Hypoglycemia Risk: The Most Clinically Significant Adverse Effect

Hypoglycemia is the primary safety concern with NPH. A meta-analysis published in Diabetes Care (N=2,304 patients across 16 randomized controlled trials) found nocturnal hypoglycemia rates of 26.7 episodes per 100 patient-years with NPH given at bedtime, compared with 11.2 episodes per 100 patient-years with insulin glargine (relative risk 2.39, P<0.001) [12]. The 4-to-12-hour peak of NPH coincides with overnight sleep in bedtime dosing schedules, explaining the differential risk.

Patients most vulnerable to NPH-related hypoglycemia include those with chronic kidney disease (CKD stages 3 to 5), older adults, and people with hypoglycemia unawareness. The ADA Standards of Care note that for these groups, long-acting analogs with flatter profiles are preferred when cost allows [7].

Recognizing early symptoms (shakiness, diaphoresis, confusion) and treating with the "15-15 rule" (15 grams of fast-acting carbohydrate, recheck in 15 minutes) is standard management [7]. Patients on NPH should carry glucose tablets or juice at all times, and close contacts should know how to administer glucagon if the patient becomes unresponsive.

NPH Insulin vs. Metformin: Different Roles, Different Patients

Metformin is an oral biguanide that suppresses hepatic glucose output and improves insulin sensitivity without stimulating insulin secretion, meaning it carries essentially no hypoglycemia risk when used alone [13]. NPH insulin, by contrast, directly replaces or supplements endogenous insulin secretion.

The two agents are not competitors for the same patient population. Metformin is the preferred first-line pharmacologic agent for type 2 diabetes according to the ADA, the AACE, and the European Association for the Study of Diabetes (EASD) [7, 11]. NPH insulin typically enters the picture when metformin plus one or two additional oral agents fail to achieve glycemic targets, or when a patient presents with markedly elevated HbA1c (>10%) or symptoms of hyperglycemia suggesting insulin deficiency [7].

The UKPDS 34 trial (N=1,704) demonstrated that metformin reduced diabetes-related mortality by 42% versus dietary management in overweight patients with type 2 diabetes (P=0.017), without the weight gain or hypoglycemia associated with insulin and sulfonylureas [14]. Adding NPH to metformin, however, is a common and effective combination: metformin continues to limit hepatic glucose production while NPH covers the absolute insulin deficit.

NPH Insulin vs. Glipizide (a Sulfonylurea)

Glipizide is a second-generation sulfonylurea that stimulates pancreatic beta cells to secrete insulin regardless of prevailing glucose levels [15]. Like NPH, it carries real hypoglycemia risk. Unlike NPH, its effect depends on residual beta-cell function, so it becomes progressively less effective as beta-cell mass declines over the natural history of type 2 diabetes.

A 2007 Veterans Affairs randomized trial (N=1,791) compared glipizide with rosiglitazone and metformin as add-on therapies. Glipizide achieved faster early glycemic control but produced more hypoglycemia (9.8% of patients vs. 1.6% with metformin) and modest weight gain (0.6 kg over 36 months) [16]. NPH insulin, by providing exogenous insulin rather than stimulating endogenous secretion, remains effective even in late-stage type 2 diabetes when beta cells are largely exhausted.

Clinicians sometimes sequence therapy as: metformin first, add glipizide second, initiate NPH basal insulin third. That progression matches the ADA's 2024 stepwise escalation framework when cardiovascular or renal disease is not present to guide selection of a GLP-1 receptor agonist or SGLT2 inhibitor instead [7].

NPH Insulin vs. Pioglitazone (Actos)

Pioglitazone is a thiazolidinedione (TZD) that activates peroxisome proliferator-activated receptor gamma (PPAR-gamma) to improve insulin sensitivity in adipose tissue, skeletal muscle, and liver [17]. The PROactive trial (N=5,238 patients with type 2 diabetes and established cardiovascular disease) showed pioglitazone reduced the composite of all-cause mortality, non-fatal myocardial infarction, and stroke by 16% versus placebo (P=0.027) [18].

However, pioglitazone causes fluid retention, which increases the risk of congestive heart failure. The FDA added a black-box warning to pioglitazone in 2011 noting that the drug is contraindicated in patients with NYHA Class III or IV heart failure [19]. NPH insulin does not carry a heart failure contraindication, though insulin itself can cause or worsen edema through sodium retention.

Pioglitazone also consistently causes weight gain (mean 3 to 5 kg over 6 months), as does NPH insulin when glycemic control improves (caloric conservation from reduced glucosuria). The two agents are sometimes combined: pioglitazone addresses insulin resistance while NPH covers the absolute secretory deficit. The ADA notes this combination is effective but increases edema risk and should be avoided in patients with a history of heart failure [7].

NPH Insulin vs. Empagliflozin (Jardiance)

Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal tubule, causing glycosuria and lowering blood glucose independently of insulin [20]. The EMPA-REG OUTCOME trial (N=7,020 patients with type 2 diabetes and established cardiovascular disease) showed empagliflozin 10 mg reduced cardiovascular death by 38% (hazard ratio 0.62 to 95% CI 0.49 to 0.77, P<0.001) and hospitalization for heart failure by 35% versus placebo [21].

Empagliflozin also reduces HbA1c by 0.5 to 0.7 percentage points as monotherapy, which is modest compared with the HbA1c reductions achievable with adequate insulin doses. It is not a replacement for insulin in insulin-deficient states. In fact, using SGLT2 inhibitors in insulin-dependent patients (including type 1 diabetes) without dose adjustment increases the risk of euglycemic diabetic ketoacidosis, a potentially life-threatening complication [22].

For type 2 patients with established cardiovascular disease or heart failure, current ADA guidance prioritizes empagliflozin or another SGLT2 inhibitor regardless of HbA1c [7]. In that population, adding empagliflozin to an NPH-based regimen may allow a meaningful insulin dose reduction while providing cardiorenal protection the insulin itself cannot offer.

HealthRX Clinical Decision Framework: When to Choose NPH vs. Modern Alternatives

| Clinical Scenario | Preferred Option | NPH Role | |---|---|---| | Type 2, newly diagnosed, HbA1c 7 to 9%, no CVD | Metformin monotherapy | Not first-line | | Type 2, HbA1c >10% or symptomatic hyperglycemia | Basal insulin initiation | NPH is cost-effective choice | | Type 2 with established heart failure | Empagliflozin or dapagliflozin | Add NPH only if HbA1c remains >9% | | Type 2, low income, uninsured | OTC NPH (ReliOn Novolin N) | Primary basal insulin | | Type 1 diabetes, any income level | Basal-bolus with analogs preferred; NPH if cost-limited | Acceptable with regular insulin | | Pregnancy (gestational or preexisting) | NPH is preferred human insulin in pregnancy | First-line basal insulin |

NPH in Pregnancy and Gestational Diabetes

NPH insulin is the preferred basal insulin in pregnancy because it has the longest safety record in obstetric populations. Insulin analogs glargine and detemir have FDA Pregnancy Category C designations, while NPH carries Category B based on animal reproduction studies and decades of clinical use [5].

The American College of Obstetricians and Gynecologists (ACOG) 2018 gestational diabetes guideline recommends starting insulin when fasting glucose consistently exceeds 95 mg/dL or 1-hour postprandial glucose exceeds 140 mg/dL despite dietary management, and lists NPH as an acceptable basal choice [23]. Insulin requirements rise substantially across the second and third trimesters, often by 50 to 100 percent above pre-pregnancy doses, requiring frequent dose adjustments.

Postpartum, insulin sensitivity improves rapidly. Patients managed with NPH during pregnancy typically need dose reductions of 30 to 50 percent within 24 to 48 hours of delivery to avoid hypoglycemia [23].

Storage, Administration Technique, and Common Errors

NPH is a suspension, not a solution. The vial or pen appears cloudy, and the white precipitate must be resuspended before each injection by rolling the vial gently between the palms 10 times. Shaking causes bubbles that alter dose accuracy [3].

Unopened vials and pens should be stored refrigerated at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). An in-use vial kept at room temperature (below 77 degrees Fahrenheit) is stable for 28 days. Exposure to temperatures above 86 degrees Fahrenheit or direct sunlight degrades the insulin and reduces its potency [3].

Injection sites should be rotated systematically within the same anatomic region (abdomen, thigh, upper arm, or buttock). Abdomen gives the fastest and most consistent absorption; thigh and buttock give slower, more variable absorption, which may help flatten the NPH peak for some patients [1]. Lipohypertrophy at repeatedly used sites slows absorption unpredictably and is a common, underappreciated cause of erratic glycemic control [24].

Monitoring Targets and Titration Schedule

Patients on NPH should monitor fasting blood glucose daily and 2-hour postprandial glucose at least 2 to 3 times per week. The ADA recommends fasting targets of 80 to 130 mg/dL and postprandial targets <180 mg/dL for most non-pregnant adults [7].

A simple bedtime NPH titration protocol from the 2009 LANMET trial (N=110, type 2 diabetes) increased NPH doses by 2 units every 3 days until fasting glucose reached 72 to 90 mg/dL, achieving a mean HbA1c reduction of 1.9 percentage points over 36 weeks with a low rate of severe hypoglycemia (0.9 episodes per patient-year) [25]. The key principle: titrate based on fasting glucose, not HbA1c, because HbA1c lags 8 to 12 weeks behind actual glycemic changes.

HbA1c should be measured every 3 months until the target is stable, then every 6 months [7]. Continuous glucose monitors (CGMs) can identify nocturnal hypoglycemia that fingerstick testing misses; the ADA recommends offering CGM to any adult using insulin, including those on NPH [7].